摘要
嘌呤信号调节中枢神经系统(CNS)的许多重要的生物过程。ATP和腺苷这两个原则嘌呤分别充当兴奋性和抑制性神经递质。相比于其他经典神经递质,嘌呤信号在精神疾病中的作用尚不十分清楚或被理解。由于ATP主要在能量平衡上发挥它的主要作用,ATP的神经元功能已被低估。同样地,腺苷主要被看做是活性细胞生长和分裂过程中核苷酸的合成的前体。然而,最近的研究结果表明,嘌呤信号可能解释神经元活动是如何与神经元能荷和能量平衡相关联的,特别是在精神障碍疾病中。在这篇综述中,我们提供了关于线粒体和嘌呤在神经调节,突触可塑性和神经元与神经胶质相互作用中的突触功能的概述。我们总结了线粒体和嘌呤功能障碍是如何促进精神疾病如精神分裂症、躁郁症、自闭症谱系障碍(ASD)抑郁症和成瘾性。最后,我们讨论了有关的线粒体的药理学靶点和嘌呤功能对于精神疾病的治疗的未来的影响。
关键词: 腺苷,ATP,能量平衡,精神障碍,线粒体,谷氨酸盐,嘌呤
Current Molecular Medicine
Title:Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Volume: 15 Issue: 3
Author(s): D. Lindberg, D. Shan, J. Ayers-Ringler, A. Oliveros, J. Benitez, M. Prieto, R. McCullumsmith and D.-S. Choi
Affiliation:
关键词: 腺苷,ATP,能量平衡,精神障碍,线粒体,谷氨酸盐,嘌呤
摘要: Purinergic signaling regulates numerous vital biological processes in the central nervous system (CNS). The two principle purines, ATP and adenosine act as excitatory and inhibitory neurotransmitters, respectively. Compared to other classical neurotransmitters, the role of purinergic signaling in psychiatric disorders is not well understood or appreciated. Because ATP exerts its main effect on energy homeostasis, neuronal function of ATP has been underestimated. Similarly, adenosine is primarily appreciated as a precursor of nucleotide synthesis during active cell growth and division. However, recent findings suggest that purinergic signaling may explain how neuronal activity is associated neuronal energy charge and energy homeostasis, especially in mental disorders. In this review, we provide an overview of the synaptic function of mitochondria and purines in neuromodulation, synaptic plasticity, and neuron-glia interactions. We summarize how mitochondrial and purinergic dysfunction contribute to mental illnesses such as schizophrenia, bipolar disorder, autism spectrum disorder (ASD), depression, and addiction. Finally, we discuss future implications regarding the pharmacological targeting of mitochondrial and purinergic function for the treatment of psychiatric disorders.
Export Options
About this article
Cite this article as:
D. Lindberg, D. Shan, J. Ayers-Ringler, A. Oliveros, J. Benitez, M. Prieto, R. McCullumsmith and D.-S. Choi , Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders, Current Molecular Medicine 2015; 15 (3) . https://dx.doi.org/10.2174/1566524015666150330163724
DOI https://dx.doi.org/10.2174/1566524015666150330163724 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 4
Current Pharmaceutical Biotechnology Pharmacological Activities and Therapeutic Potential of Kaempferitrin in Medicine for the Treatment of Human Disorders: A Review of Medicinal Importance and Health Benefits
Cardiovascular & Hematological Disorders-Drug Targets Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design New Alkyl-Lipid Blockers of SK3 Channels Reduce Cancer Cell Migration and Occurrence of Metastasis
Current Cancer Drug Targets New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry Nanoparticle-mediated Drug Delivery Systems (DDS) in the Central Nervous System
Current Organic Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry A Validated Mathematical Model of Tumour-Immune Interactions for Glioblastoma
Current Medical Imaging Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Gene Therapy Using an Adenovirus Vector for Apoptosis-Related Genes is a Highly Effective Therapeutic Modality for Killing Glioma Cells
Current Gene Therapy